Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 89.26M P/E 4.63 EPS this Y -91.30% Ern Qtrly Grth -
Income -14.11M Forward P/E -12.91 EPS next Y 115.90% 50D Avg Chg 7.00%
Sales 16.45M PEG - EPS past 5Y - 200D Avg Chg 13.00%
Dividend N/A Price/Book 2.16 EPS next 5Y - 52W High Chg -35.00%
Recommedations 2.00 Quick Ratio 10.41 Shares Outstanding 26.20M 52W Low Chg 130.00%
Insider Own 7.34% ROA -21.35% Shares Float 24.52M Beta 0.30
Inst Own 10.35% ROE -36.01% Shares Shorted/Prior 1.10M/0.99M Price 4.26
Gross Margin -6.70% Profit Margin -85.75% Avg. Volume 250,806 Target Price 16.75
Oper. Margin -748.92% Earnings Date Nov 11 Volume 92,561 Change 2.16%
About Ocuphire Pharma, Inc.

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Ocuphire Pharma, Inc. News
11/14/24 Opus Genetics reinstated with a Buy at H.C. Wainwright
11/12/24 Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/25/24 The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics
10/23/24 Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics
10/22/24 Ocuphire Pharma Announces Acquisition of Opus Genetics
09/30/24 Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology
09/05/24 UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
09/05/24 Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia
08/16/24 Ocuphire Pharma, Inc. (NASDAQ:OCUP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
08/13/24 Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update
08/08/24 Ocuphire Pharma to Present at Two Investor Conferences in August
08/01/24 Here's Why We're Not At All Concerned With Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
07/10/24 Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
06/06/24 Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
05/12/24 Ocuphire Pharma First Quarter 2024 Earnings: Misses Expectations
05/10/24 Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
05/06/24 Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
05/03/24 Ocuphire Pharma to Present at the Aegis Virtual Conference
04/22/24 Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
04/11/24 First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
OCUP Chatroom

User Image JussieLivermore Posted - 1 day ago

$OCUP As I shared with this group before, I hired a consultant to conduct interviews with knowledgeable VTRS employees about the poor Ryzumvi sales. The short answer, they are waiting for another approved indication before big investment. Facts since that research, VTRS recent earnings release mentioned the phentolamine P3 readouts next year. George has twice mentioned expectations of significant phentolamine cash flows. It is a shame all we get is a sentence here or there and not more articulation of why George is making this statement. Why does the company think they can generate presbyopia revenue when LENZ looks great. I think I know, but I am a lowly investor. APX3330 is another topic I could rail about, it has been a year since George first mentioned they were considering all alternatives, yet nothing. Certainly, the acquisition and the departure of a key executive slowed development; however, investors need more information. After all, George crowed about this.

User Image Bakhmutbull2 Posted - 1 day ago

$OCUP I hope the BOD all buy 100k shares each. It might help, maybe.

User Image JussieLivermore Posted - 1 day ago

$OCUP Let's get more insider buying. Board members, COO/CFO/President/SVP Finance, you need to step up and buy.

User Image JussieLivermore Posted - 1 day ago

$OCUP So George bought 100k shares? WTF? After selling? SEC call, sorry, my bad, I will buy back 3 times as much?

User Image Novice1a Posted - 1 day ago

$OCUP does this mean we all just bought George another 100 thousand shares?

User Image Novice1a Posted - 2 days ago

$OCUP https://ir.stockpr.com/opusgtx/sec-filings-email/content/0000905148-24-003236/form4.html jerk

User Image Bakhmutbull2 Posted - 2 days ago

$OCUP Dumpster fire. Everyone at HQ high fives for a plan that came together. I'm considering selling my 1 share and save a quarter

User Image JoeD32 Posted - 2 days ago

$OCUP down 25 percent in 5 days and nothing from the leaders of this ”company” 🤣

User Image Maynard_Keysian Posted - 2 days ago

$OCUP About a year ago the company had an investor call, time for another one. This time take pre-submitted questions from retail shareholders since we own about 85% of the company. And the analyst ask pathetic questions and don't own any of the stock.

User Image alexquick123 Posted - 2 days ago

$OCUP 50 cent price target, reverse split then lifted from their

User Image TickrTalk0007 Posted - 2 days ago

$OCUP If you go after gene therapy ror rare diseases then dont go full retard and say you have an ryzumvi that will make hundreds of millions to pay for the gene tx with $15k in royalties 😂 dumb deal that diluted ocup legacy shareholders by almost 100% the entire board and mgmt needs to get thrown out.

User Image JussieLivermore Posted - 2 days ago

$OCUP Well at least I was prepared and managed accordingly. George is an idiot and needs to be fired. Cam and Rick Rodgers as well.

User Image JussieLivermore Posted - 2 days ago

$OCUP George Magrath is a eunuch.

User Image JussieLivermore Posted - 2 days ago

$OCUP Everyone has been George Magrath(ed), worst CEO in America. The pathetic leader sold before earnings and released earnings with a statement suggesting the failed Ryzumvi is expected to generate significant cash flow in the future. The coward won’t bother to try to explain to shareholders how this is magic thinking is supposed to happen. A big shareholder dumped today and made a statement that George’s has no credibility.

User Image Rush__2112 Posted - 3 days ago

$OCUP does anybody have any idea why it’s dropping like a rock. Almost 600,000 Shares traded so there’s some sort of news out that’s not good. Not to be cliché, but somebody knows something.

User Image JoeD32 Posted - 3 days ago

$OCUP $6 to 89 cents what a run

User Image GladEator Posted - 3 days ago

$OCUP

User Image JussieLivermore Posted - 3 days ago

$OCUP Opus transactions related?

User Image Bakhmutbull2 Posted - 3 days ago

$OCUP Meanwhile as HQ searches for the SPA documents on lost carrier pigeon, Lenz sporting $950 million MC.

User Image JoeD32 Posted - 3 days ago

$OCUP 50 cents this week then I can buy

User Image JussieLivermore Posted - 3 days ago

$OCUP Heavy selling at lows, did George get a call regarding his selling prior to earnings, is he dumping the rest of his shares, market giving up on the loser or something else?

User Image JoeD32 Posted - 3 days ago

$OCUP on the steady road to dump city…I’m sure everyone on the board has dumped their shares by now

User Image Novice1a Posted - 3 days ago

$OCUP A partnership for a biotech company can be incredibly valuable, potentially worth millions or even billions of dollars, depending on the stage of the biotech company's development, the quality of its technology, the partner's capabilities, and the terms of the deal, which could include upfront payments, milestone payments, royalties on future sales, and access to crucial expertise and infrastructure for drug development and commercialization.

User Image JussieLivermore Posted - 6 days ago

$OCUP Give me your shares below $1

User Image texasdeb Posted - 6 days ago

$OCUP this is ridiculous- need Mina Sooch back stat -

User Image JoeD32 Posted - 6 days ago

$OCUP when do they do the reverse split to meet the price target of $8?

User Image JoeD32 Posted - 6 days ago

$OCUP lower highs and lower lows…pump it to the floor

User Image Maynard_Keysian Posted - 1 week ago

$OCUP This is a valid point. The small company has a CEO, COO, President, CFO and SVP Finance, yet is unable to communicate with its shareholders. Comparatively, LENZ holds quarterly earnings calls. No wonder the market rewards LENZ with a much higher valuation. We need a leadership team with testicular fortitude.

User Image JoeD32 Posted - 1 week ago

$OCUP

User Image JoeD32 Posted - 1 week ago

$OCUP under a buck by weeks end…25 more cents and ill buy again

Analyst Ratings
HC Wainwright & Co. Buy Aug 15, 24
Canaccord Genuity Buy Aug 14, 24
Canaccord Genuity Buy May 13, 24
HC Wainwright & Co. Buy May 13, 24
Alliance Global Partners Buy Mar 20, 24
HC Wainwright & Co. Buy Mar 11, 24
HC Wainwright & Co. Buy Nov 14, 23
Cantor Fitzgerald Overweight Aug 14, 23
HC Wainwright & Co. Buy Aug 14, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
MANUSO JAMES S J Director Director May 20 Buy 1.99 5,000 9,950 21,570 05/24/22